Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH
The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH.
- EligibilityCriteria: Inclusion Criteria:  A subject aged ≥19 years to ≤75 years  Meeting all of the following criteria:  Screening MRI-PDFF with ≥8% steatosis Screening MRE with liver stiffness ≥2.5 kPa ALT or AST ≤250 IU/L at screening Willing to maintain the same lifestyle (exercise, alcohol consumption, diet, etc.) during the study Voluntarily provide written consent to participate in the study  Exclusion Criteria:  A subject who has past or current history of liver diseases  A subject who has the following medical or surgical history  Severe cardiac diseases, Malignant tumors, Clinically significant hypersensitivity reaction to any drugs containing components of the 11β-HSD1 inhibitor or same class  A subject who has the following concomitant diseases  liver disease, uncontrolled hypertension, uncontrolled DM, etc.  A subject who has taken the following medications  Systemic glucocorticoids, NSAIDs, any medication that may induce fatty liver disease, etc. A subject who has taken IP of another study A subject who does not agree with appropriate methods of contraception - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult